Loading
Maat Pharma Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 29 May 2026.
Maat Pharma: what insiders have been doing
Maat Pharma, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to AMF. 3 insiders have disclosed 10 filings since 18 October 2025.
Purchases and sales both appear in the filings: 3 purchases (1 insider, €16k) and 6 sales (1 insider, €1.3M). Taken together, the sales exceed the purchases by €1.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 chief executive. Biggest ticket of the year: €438k, sold by Seventure Partners Societe Anonyme A Directoire and made public on 8 January 2026.
Across the 316 companies tracked on its exchange, the median is 6 filings; at 10 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 13 purchases and 38 sales.
The clock since the last published purchase (29 May 2026) now reads 141 days. Filings reach the AMF feed a median of 2 days after the trade. The legal deadline for notifying a trade is three business days (MAR article 19). A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
59
Thresholds
n/a
Buy Volume
€1M
13 ops. · all time
Sell Volume
€3M
38 ops. · all time
Who traded when
BuySaleSEVENTURE PARTNERS societe anonyme a directoire22 sales
Herve Affagard3 buys
Since the insiders bought
- -0.2%Entry €2.96 · Close at T+90 €2.96
- -39.2%Entry €8.14 · Close at T+365 €4.95
- -39.2%Entry €8.14 · Close at T+365 €4.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Maat Pharma Buy (bullish), based on 2 analysts. Average price target: €6.50.
Financial data
as of FY 2025FY ended December 2025 · cache
€1.36
Analyst consensus
2 analystsBuy
€3.00Target €6.50(+379%)€10.00
Income statement
Revenue€4.5M
Gross profit€3.1M69% margin
EBITDA-€28.1M-620% margin
Net income-€31.1M-686.6% margin
Valuation
PER (forward)-1.2x
P/Book14.1x
Beta0.41
Balance sheet & cash
Market cap€25.6M
Total debt€15.4M
Free Cash Flow-€16.3M
Debt / Equity969%
Profitability & ownership
ROE-511.9%
ROA-44.7%
% insiders22.1%
% institutions46.6%
Last declaration on 29 May 2026
Declarations59 total
2,000 shares@ €2.790.010% mcap3.5% of flowActionEuronext ParisISIN FR00126348222026DD1117103
Canonical exit: 26 Aug 2026 (T+90)
25,423 shares@ €6.1112.2% of flowActionEuronext ParisISIN FR00126348222026DD1091318
57,964 shares@ €6.0627.6% of flowActionEuronext ParisISIN FR00126348222026DD1091222
19,624 shares@ €5.08277.8% of flowActionEuronext ParisISIN FR00126348222026DD1088776
24,304 shares@ €5.388110.3% of flowActionEuronext ParisISIN FR00126348222026DD1088355
81,190 shares@ €5.398634.5% of flowActionEuronext ParisISIN FR00126348222026DD1088050
16,895 shares@ €5.15786.9% of flowActionEuronext ParisISIN FR00126348222026DD1087751
2,600 shares@ €3.485.6% of flowActionEuronext ParisISIN FR00126348222025DD1071415
Canonical exit: 16 Feb 2026 (T+90)
430 shares@ €3.480.9% of flowActionEuronext ParisISIN FR00126348222025DD1070840
Canonical exit: 16 Feb 2026 (T+90)
431,034 shares@ €3.486.4% of flowActionHors plateforme de négociationISIN FR00126348222025DD1070137
819,672 shares@ €6.1021.2% of flowActionEuronext ParisISIN FR00126348222025DD1028072
104 shares@ €8.0160.0% of flowActionEuronext ParisISIN FR00126348222025DD1018335
46 shares@ €8.10170.0% of flowActionEuronext ParisISIN FR00126348222025DD1018054
515 shares@ €8.02630.2% of flowActionEuronext ParisISIN FR00126348222025DD1017875
407 shares@ €8.01460.1% of flowActionEuronext ParisISIN FR00126348222025DD1017413
398 shares@ €8.02920.1% of flowActionEuronext ParisISIN FR00126348222025DD1017136
361 shares@ €8.18850.1% of flowActionEuronext ParisISIN FR00126348222025DD1016915
1,278 shares@ €8.31520.4% of flowActionEuronext ParisISIN FR00126348222025DD1016732
367 shares@ €8.33040.1% of flowActionEuronext ParisISIN FR00126348222025DD1016734
1,599 shares@ €8.16530.5% of flowActionEuronext ParisISIN FR00126348222025DD1016429
946 shares@ €8.01320.3% of flowActionEuronext ParisISIN FR00126348222025DD1016076
542 shares@ €8.01170.2% of flowActionEuronext ParisISIN FR00126348222025DD1015907
550 shares@ €8.06110.2% of flowActionEuronext ParisISIN FR00126348222025DD1015693
12,564 shares@ €8.03163.7% of flowActionEuronext ParisISIN FR00126348222025DD1015398
404 shares@ €8.07290.1% of flowActionEuronext ParisISIN FR00126348222025DD1015307
25 of 59 declarations
About Maat Pharma
MaaT Pharma is a French clinical-stage biotechnology company listed on Euronext Paris under the ticker MAAT and ISIN FR0012634822. Built around a highly specialized scientific expertise in the microbiome, the company focuses on microbiome-based biotherapies and aims to improve survival outcomes for cancer patients through immune modulation. MaaT Pharma was listed on November 8, 2021, a milestone that enhanced its market visibility and financing capacity.
The company’s core platform is its proprietary Microbiome Ecosystem Therapies™ (MET) approach, designed to restore gut microbiome balance and support immune response. Its business is centered on clinical development rather than broad commercial sales, with a strong focus on high-unmet-need oncology and hematology settings. Its lead asset, Xervyteg® (MaaT013), has been developed for severe indications in medically fragile patients, while MaaT033 is currently being evaluated in a potentially pivotal Phase 2b trial. This clinical pipeline reflects a strategy built around scientifically differentiated, value-creating milestones.
Read moreShow less
MaaT Pharma has established a niche position at the intersection of microbiology, immunology and oncology. It stands out as one of the few European listed companies pursuing microbiome-derived therapies for cancer-related complications, in an emerging market that remains early but structurally attractive. A key operational achievement was the completion, with Skyepharma, of what the company described as Europe’s largest manufacturing facility dedicated to Microbiome Ecosystem Therapies. This manufacturing footprint supports both clinical supply and the potential transition toward commercialization.
Geographically, MaaT Pharma is headquartered in France but has an international operating profile. Its clinical development, partnerships and regulatory interactions are largely Europe-oriented, while the commercial strategy is being prepared for broader market access. In 2025, the company signed an exclusive license and distribution agreement with Clinigen to support European patient access to Xervyteg® if marketing authorization is obtained, highlighting the company’s step-by-step commercialization model. MaaT Pharma is also followed by several analysts and is widely viewed as a reference French biotech name, with its investment case driven by clinical execution, regulatory progress and financing milestones.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
